Neuphoria Therapeutics (NEUP) Depreciation & Amortization (CF) (2023 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Depreciation & Amortization (CF) of $165695.0 for Q1 2026, little changed year-over-year from $165431.0 in Q1 2025, and little changed quarter-over-quarter from $165789.0 in Q4 2025.
Neuphoria Therapeutics (NEUP) Depreciation & Amortization (CF) (2023 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Depreciation & Amortization (CF) for 4 consecutive years, with $165695.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) changed 0.16% year-over-year to $165695.0; the TTM figure through Mar 2026 stood at $662901.0 (changed 0.01% YoY), while the FY2025 annual figure was $662890.0, changed 0.02% from the prior year.
- Depreciation & Amortization (CF) held at $165695.0 in Q1 2026 per NEUP's latest filing, from $165789.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $166121.0 in Q4 2024 and bottomed at $165431.0 in Q1 2025.
- Historically, Depreciation & Amortization (CF) has averaged $165741.5 across 4 years, with a median of $165703.0 in 2024.
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) advanced 0.26% — and 2025, when it decreased 0.2%.
- Neuphoria Therapeutics' Depreciation & Amortization (CF) stood at $165694.0 in 2023, then grew by 0.26% to $166121.0 in 2024, then declined by 0.2% to $165789.0 in 2025, then dropped by 0.06% to $165695.0 in 2026.
- Business Quant data shows NEUP's Depreciation & Amortization (CF) at $165695.0 in Q1 2026, $165789.0 in Q4 2025, and $165792.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Neuphoria Therapeutics | 21.28 Mn | 1.84 Mn | - | 165,695.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 165,695.00 |
| Mar 31, 2026 | 165,695.00 |
| Dec 31, 2025 | 165,789.00 |
| Dec 31, 2025 | 165,789.00 |
| Sep 30, 2025 | 165,792.00 |
| Sep 30, 2025 | 165,792.00 |
| Jun 30, 2025 | 165,625.00 |
| Jun 30, 2025 | 165,625.00 |
| Mar 31, 2025 | 165,431.00 |
| Mar 31, 2025 | 165,431.00 |
| Dec 31, 2024 | 166,121.00 |
| Dec 31, 2024 | 166,121.00 |
| Sep 30, 2024 | 165,713.00 |
| Sep 30, 2024 | 165,713.00 |
| Jun 30, 2024 | 165,685.00 |
| Jun 30, 2024 | 165,685.00 |
| Mar 31, 2024 | 165,703.00 |
| Mar 31, 2024 | 165,703.00 |
| Dec 31, 2023 | 165,694.00 |
| Dec 31, 2023 | 165,694.00 |